Glutamate receptors in laryngeal cancer cells

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Andrzej Stepulak - , Medical University of Lublin, MSWiA Hospital (Author)
  • Hella Luksch - , Department of Paediatrics (Author)
  • Ortrud Uckermann - , Department of Paediatrics (Author)
  • Marco Sifringer - , Charité – Universitätsmedizin Berlin (Author)
  • Wojciech Rzeski - , Maria Curie-Skłodowska University in Lublin, Witold Chodźki Institute of Rural Medicine (Author)
  • Krzysztof Polberg - , MSWiA Hospital (Author)
  • Krzysztof Kupisz - , Specialist District Hospital (Author)
  • Janusz Klatka - , Medical University of Lublin (Author)
  • Michał Kiełbus - , Medical University of Lublin (Author)
  • Aneta Grabarska - , Medical University of Lublin (Author)
  • Jenny Marzahn - , TUD Dresden University of Technology (Author)
  • Lechoslaw Turski - , Solvay S.A. (Author)
  • Chrysanthy Ikonomidou - , University of Wisconsin-Madison (Author)

Abstract

Aim: Despite recent improvements in treatment strategies, the results of chemotherapy in patients with advanced squamous cell carcinoma of the larynx are not satisfactory. Thus, the development of new approaches which influence specific metabolic pathways are needed. In the last decade, evidence has emerged implicating a role for glutamate as a signal mediator in tumors. Materials and Methods: The presence of glutamate receptor subunits in two laryngeal cancer cell lines (RK33 and RK45) was evaluated by means of end-point PCR, real-time PCR, and immunocytochemistry. Results: Glutamate receptor subunits are differentially expressed in laryngeal cancer cell lines. In addition, we show that selected ionotropic glutamate receptor antagonists and metabotropic glutamate receptor 5 antagonist inhibit proliferation of laryngeal cancer cells. Glutamate antagonists also affected activity of extracellular signal-regulated kinases 1/2 in tumor cells. Conclusion: Signaling through glutamate receptors may influence growth of laryngeal cancer cells and may constitute an adjunctive therapeutic target.

Details

Original languageEnglish
Pages (from-to)565-573
Number of pages9
JournalAnticancer research
Volume31
Issue number2
Publication statusPublished - Feb 2011
Peer-reviewedYes

External IDs

PubMed 21378340

Keywords

Sustainable Development Goals

ASJC Scopus subject areas

Keywords

  • Antagonist, ERK1/2 kinase, Glutamate receptor, Laryngeal cancer, Proliferation